LDS/Medical Tests/Oncology Pharmacogenetics (PGx) Gene Variation Panel

Oncology Pharmacogenetics (PGx) Gene Variation Panel

Several studies have shown that genetic predisposition accounts for a larger role in cancer development, progression, and response to therapy. Years of extensive genetic research have shown that certain genes are now shown to be associated with a wide variety of cancers. Furthermore, the presence of specific genetic polymorphisms is responsible for poor or favored response or toxic effects of chemotherapy. Pharmacogenetic screening of such genes is often useful in predicting the individual patient response to chemotherapy. Testing for these gene variations aids in the appropriate selection of a personalized medication regimen, and overall helps overcome the possibility of treatment failure. Considering the narrow therapeutic index of drugs for oncology and the need of elucidating the neoplasm, it is therefore vital to accurately select and administer the appropriate drug.

Multiple studies demonstrate specific drug-gene pairs that impact the delivery of oncology medication. For instance, tamoxifen and the gene CYP2D6 have a direct pharmacokinetic relationship, and individuals with this genotype favor a positive response to tamoxifen. These genes or gene variants are often termed ‘pharmacogenetic markers and testing of these markers all together via multiplex PCR, or next-generation sequencing enables significantly improved prediction of therapeutic response to prescribed medication. CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, MTHFR, NUDT15, TPMT, ABC, and ERCC are the commonly analyzed pharmacogenetic markers which are a part of the drug-gene pairs in oncology.

The following are some other drug-gene pairs and polymorphisms in these genes significantly alter the responses of subsequent drugs, either positively or negatively.

  • CYP2C19-Citalopram, Clopidogrel, Escitalopram.
  • CYP2D6- Codeine, Fluvoxamine, Fluoxetine, Tramadol, Tamoxifen, Paroxetine, Venlafaxine.
  • CYP3A5- Tacrolimus
  • TMPT- Triopurines
  • ERCC- Oxaliplatin
  • MTHFR- fluoropyrimidine
  • Aids in the selection of appropriate drugs for oncology
  • Useful in predicting the response to the targeted therapy
  • Helpful in determining recurrence, relapse, drug- toxicity, survival and mortality

A positive result indicates the presence of polymorphisms in the targeted genes and therefore indicating an altered response.

Classification can be done as:

Weak Metabolizer: Increased efficacy of active drug; active metabolite may accumulate; usually require a lower dose to avoid toxic accumulation. Decreased efficacy of prodrug; prodrug may require a lower dose to avoid toxic accumulation or require an alternate drug.

Rapid Metabolizer: Decreased efficacy of active drug; active metabolite rapidly inactivated usually requires a higher dose to offset inactivation. Increased efficacy of prodrug; rapid onset of effect, may require a lower dose to prevent excessive accumulation of active metabolite.

See individual assay.

Multiplex Polymerase Chain Reaction (PCR) and allele-specific primer extension (ARMS), Next generation sequencing (NGS), Sanger sequencing.

Whole blood (EDTA), buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Supportive clinical tests, including chemistry, hematology, and tumor markers; drug screening.
1-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login